Maynard Um
-
-
-
-
-
-
-
Why UBS says Q4 is eventful for SMID oncology stocks
-
-
-
-
-
-
-
Perspective Therapeutics Inc (CATX) PT Raised to $16 at RBC Capital
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)
-
-
-
-
-
-
-
UBS Starts Perspective Therapeutics Inc (CATX) at Buy
-
-
-
-
-
-
-
Perspective Therapeutics Inc (CATX) PT Lowered to $17 at Oppenheimer
-
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

